DALLAS–(BUSINESS WIRE)–Today, the national law firm of Baron & Budd announced that AstraZeneca has agreed to pay $110 million to settle two whistleblower lawsuits brought by the State of Texas under the Texas Medicaid Fraud Prevention Act (“TMFPA”). The first settlement, totaling $90 million, resolves allegations that AstraZeneca targeted the Texas Medicaid system with a fraudulent marketing scheme for its expensive and powerful atypical antipsychotic drugs Seroquel IR and Seroquel XR from 2007 through 2010. The second settlement for $20 million resolves allegations that AstraZeneca misrepresented and concealed information about the safety, efficacy and appropriate use of its drug Crestor to the Texas Medicaid system. AstraZeneca has denied any wrongdoing in both cases.